US drugmaker Baxter suspends Russian operations

8 May 2024

The US drugmaker Baxter (NYSE: BAX), one of the largest suppliers of dialysis solutions, has suspended its commercial activities in Russia, according to recent statements made in the company’s explanatory note to the annual financial statements of its Russian subsidiary for 2023.

Such a decision is explained by sanctions and logistics problems in the United States and Europe. In the future, Baxter plans to sell or write off the assets of its Russian company, reports The Pharma Letter’s local correspondent.

Russian analysts believe the company finally decided to leave the Russian market and is currently preparing to sell the property.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK